214 related articles for article (PubMed ID: 14749372)
1. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
[TBL] [Abstract][Full Text] [Related]
2. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
3. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
Wahlström T; Belikov S; Arsenian Henriksson M
Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
[TBL] [Abstract][Full Text] [Related]
4. Evidence of mnt-myc antagonism revealed by mnt gene deletion.
Hurlin PJ; Zhou ZQ; Toyo-Oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
Cell Cycle; 2004 Feb; 3(2):97-9. PubMed ID: 14712062
[TBL] [Abstract][Full Text] [Related]
5. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
6. Mnt takes control as key regulator of the myc/max/mxd network.
Wahlström T; Henriksson M
Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
[TBL] [Abstract][Full Text] [Related]
7. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
Yang H; Li TW; Ko KS; Xia M; Lu SC
Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
[TBL] [Abstract][Full Text] [Related]
8. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
9. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
Popov N; Wahlström T; Hurlin PJ; Henriksson M
Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
[TBL] [Abstract][Full Text] [Related]
10. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
[TBL] [Abstract][Full Text] [Related]
11. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
12. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
[TBL] [Abstract][Full Text] [Related]
13. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
[TBL] [Abstract][Full Text] [Related]
14. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
15. Mnt: master regulator of the Max network.
Nilsson JA; Cleveland JL
Cell Cycle; 2004 May; 3(5):588-90. PubMed ID: 15107624
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc.
Auvinen M; Järvinen K; Hotti A; Okkeri J; Laitinen J; Jänne OA; Coffino P; Bergman M; Andersson LC; Alitalo K; Hölttä E
Int J Biochem Cell Biol; 2003 Apr; 35(4):496-521. PubMed ID: 12565711
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Max-binding protein MNT in human medulloblastomas.
Sommer A; Waha A; Tonn J; Sörensen N; Hurlin PJ; Eisenman RN; Lüscher B; Pietsch T
Int J Cancer; 1999 Sep; 82(6):810-6. PubMed ID: 10446446
[TBL] [Abstract][Full Text] [Related]
18. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
19. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
[TBL] [Abstract][Full Text] [Related]
20. Mnt modulates Myc-driven lymphomagenesis.
Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
